section name header

Pronunciation ⬇

me-MAN-teen audio

Classifications ⬆ ⬇

Therapeutic Classification: anti-Alzheimers's agents

Pharmacologic Classification: n methyl d aspartate antagonist

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

Therapeutic Effects:

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed after oral administration.

Distribution: Unknown.

Metabolism/Excretion: 57–82% excreted unchanged in urine by active tubular secretion moderated by pH dependent tubular reabsorption. Remainder metabolized; metabolites are not pharmacologically active.

Half-life: 60–80 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown3–7 hr12 hr
PO-ERunknown9–12 hr24 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypertension.

Derm: rash.

GI: diarrhea.

GU: urinary frequency.

Hemat: anemia.

Metab: weight gain.

Neuro: dizziness, fatigue, headache, sedation.

Interactions ⬆ ⬇

Drug-Drug:

Route/Dosage ⬆ ⬇

Renal Impairment

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Namenda, Namenda XR

Canadian Brand Names ⬆ ⬇

Ebixa

Code ⬆

NDC Code*